Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Novartis acquires minority stake in Alcon
With the completion of the first step transaction, Nestle remains Alcon’s majority shareholder with approximately 52% of Alcon’s issued capital and Novartis now owns a minority stake in
With the completion of the first step transaction, Nestle remains Alcon’s majority shareholder with approximately 52% of Alcon’s issued capital and Novartis now owns a minority stake in
Patient enrolment has been completed in the first (‘lower dose’)stage of the trial, in which 33 patients were randomly assigned to be treated with either 10mg/kg/day AS1411 plus
Approximately 40 women who received radiotherapy following conservative breast cancer surgery were randomized to receive either Xclair cream (22 patients), or a cream containing a control vehicle (18
Under the terms of the agreement, IntraNexus will OEM and integrate the ProMed Series of Healthcare Solutions including ProMed DM (Document Management), ProMed Scanning, HIM Coding/Charge Entry, ProMed
The focus of the program is to select compounds using its proprietary Alzheimer’s disease (AD) screening assays active against tau oligomers, and to evaluate these compounds in a
Based on preclinical pharmacology testing and the results of completed 13-week GLP animal toxicology studies, Anadys has received clearance to initiate a clinical trial of ANA773, the company’s
Sectra PACS (system for handling radiology images) will serve in a totally integrated radiology solution incorporated into the hospitals’ existing IT infrastructure. The order comprises Sectra PACS products
Prior to joining Cell Biosciences, Mr Novi served as vice president of finance at Nektar Therapeutics. The company has also appointed Robert Gavin as its new vice president
BD Diagnostics’s GeneOhm Cdiff molecular assay is said to be the first Clostridium difficile infection (CDI) diagnostic test that offers sensitivity, simplicity and speed in one test procedure.
Under the terms of the agreement, Fresenius will acquire the outstanding common stock of APP for $23 in cash per share plus a contingent value right (CVR) that